BRAF and melanoma: Transitioning from binary to scored mutations not only resolved BRAF V600X from other BRAF mutations, but found additional mutations highly predictive of dabrafenib responses in both cell lines and melanoma patients (Figs 3a, 3b, 4b, 4c).